{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T03:00:29Z","timestamp":1790391629054,"version":"4.1.0"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,10,16]],"date-time":"2020-10-16T00:00:00Z","timestamp":1602806400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,10,16]],"date-time":"2020-10-16T00:00:00Z","timestamp":1602806400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81502003"],"award-info":[{"award-number":["81502003"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81602038"],"award-info":[{"award-number":["81602038"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81772511"],"award-info":[{"award-number":["81772511"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The aim of this study was to explore the utility of circulating free DNA (cfDNA) in the evaluation of clinical tumor burden and survival in Chinese patients with metastatic colorectal cancer (mCRC) and to preliminarily summarize some metastatic characteristics associated with mutational status.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      A panel covering a total of 197 hotspot mutations of\n                      <jats:italic>KRAS, NRAS, BRAF<\/jats:italic>\n                      and\n                      <jats:italic>PIK3CA<\/jats:italic>\n                      was used to evaluate the mutational status in plasma by next-generation sequencing (NGS) technology in 126 patients with mCRC. An amplification-refractory mutation system (ARMS) was used to analyze genomic DNA from matched tissue samples. Clinical markers including carcinoembryonic antigen (CEA), carbohydrate antigen 199 (CA199), carbohydrate antigen 125 (CA125), neuron-specific enolase (NSE) and lactate dehydrogenase (LDH) in serum and the sum of all tumor diameters on CT or PET\/CT were collected to indicate clinical tumor burden. The correlations between cfDNA and clinical tumor burden were analyzed using Pearson correlation and linear regression models. The median progression-free survival (PFS) and 1-year overall survival (OS) rates were calculated by Kaplan-Meier (K-M) survival analysis.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Of the 126 enrolled patients, patients who were tested positive for mutations in plasma accounted for 45.2% (57\/126). Mutations in\n                      <jats:italic>KRAS, NRAS, BRAF<\/jats:italic>\n                      and\n                      <jats:italic>PIK3CA<\/jats:italic>\n                      were detected in 37.3% (47\/126), 1.6% (2\/126), 3.2% (4\/126) and 13.5% (17\/126) of patients, respectively. The overall concordance rate of mutational status between plasma and matched tissues was 78.6% (99\/126). Sixteen patients had mutations in plasma that were not detected in tissue, including some rare hotspot mutations. The cfDNA concentration was significantly correlated with the levels of clinical markers, especially CEA (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.0001, Pearson\n                      <jats:italic>r<\/jats:italic>\n                      \u2009=\u20090.81), LDH (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.0001, Pearson\n                      <jats:italic>r<\/jats:italic>\n                      \u2009=\u20090.84) and the sum of tumor diameters (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.0001, Pearson\n                      <jats:italic>r<\/jats:italic>\n                      \u2009=\u20090.80). Patients with a high cfDNA concentration (&gt;\u200917.91\u2009ng\/ml) had shorter median progression-free survival (6.6 versus 11.7\u2009months,\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.0001) and lower 1-year overall survival rate (56% versus 94%,\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.0001) than those with a low cfDNA concentration (\u226417.91\u2009ng\/ml). The most common metastatic site was the liver (77.8%), followed by the lymph nodes (62.7%), lung (40.5%), peritoneum (14.3%) and bone (10.3%), in all patients. There was no significant difference in metastasis between different mutational statuses.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Analyzing mutations in plasma could provide a more comprehensive overview of the mutational landscape than analyzing mutations in tissue. The cfDNA concentration could be a quantitative biomarker of tumor burden and could predict survival in Chinese patients with mCRC.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12885-020-07516-7","type":"journal-article","created":{"date-parts":[[2020,10,16]],"date-time":"2020-10-16T05:03:30Z","timestamp":1602824610000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":29,"title":["Role of circulating free DNA in evaluating clinical tumor burden and predicting survival in Chinese metastatic colorectal cancer patients"],"prefix":"10.1186","volume":"20","author":[{"given":"Xiaojing","family":"Xu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiyi","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minna","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengling","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shengchao","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenlu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8604-6311","authenticated-orcid":false,"given":"Tianshu","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,10,16]]},"reference":[{"issue":"4","key":"7516_CR1","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1001\/jamaoncol.2016.5688","volume":"3","author":"C Fitzmaurice","year":"2017","unstructured":"Fitzmaurice C, Allen C, Barber RM, Barregard L, Bhutta ZA, Brenner H, et al. Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 32 cancer groups, 1990 to 2015: a systematic analysis for the global burden of disease study. Jama Oncol. 2017;3(4):524\u201348.","journal-title":"Jama Oncol"},{"issue":"4","key":"7516_CR2","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1038\/nrc.2017.7","volume":"17","author":"J Wan","year":"2017","unstructured":"Wan J, Massie C, Garcia-Corbacho J, Mouliere F, Brenton JD. Caldas Cet al. Liquid biopsies come of age: towards implementation of circulating tumour DNA. Nat Rev Cancer. 2017;17(4):223\u201338.","journal-title":"Nat Rev Cancer"},{"issue":"4","key":"7516_CR3","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1038\/nm.3511","volume":"20","author":"AR Thierry","year":"2014","unstructured":"Thierry AR, Mouliere F, El MS, Mollevi C, Lopez-Crapez E, Rolet F, et al. Clinical validation of the detection of KRAS and BRAF mutations from circulating tumor DNA. Nat Med. 2014;20(4):430\u20135.","journal-title":"Nat Med"},{"issue":"6","key":"7516_CR4","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.1093\/annonc\/mdx125","volume":"28","author":"J Vidal","year":"2017","unstructured":"Vidal J, Muinelo L, Dalmases A, Jones F, Edelstein D, Iglesias M, et al. Plasma ctDNA RAS mutation analysis for the diagnosis and treatment monitoring of metastatic colorectal cancer patients. Ann Oncol. 2017;28(6):1325\u201332.","journal-title":"Ann Oncol"},{"key":"7516_CR5","doi-asserted-by":"publisher","first-page":"13665","DOI":"10.1038\/ncomms13665","volume":"7","author":"BO Van Emburgh","year":"2016","unstructured":"Van Emburgh BO, Arena S, Siravegna G, Lazzari L, Crisafulli G, Corti G, et al. Acquired RAS or EGFR mutations and duration of response to EGFR blockade in colorectal cancer. Nat Commun. 2016;7:13665.","journal-title":"Nat Commun"},{"issue":"2","key":"7516_CR6","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228\u201347.","journal-title":"Eur J Cancer"},{"issue":"4","key":"7516_CR7","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1136\/gutjnl-2014-308859","volume":"65","author":"T Reinert","year":"2016","unstructured":"Reinert T, Scholer LV, Thomsen R, Tobiasen H, Vang S, Nordentoft I, et al. Analysis of circulating tumour DNA to monitor disease burden following colorectal cancer surgery. Gut. 2016;65(4):625\u201334.","journal-title":"Gut."},{"issue":"12","key":"7516_CR8","doi-asserted-by":"publisher","first-page":"2642","DOI":"10.1002\/ijc.30620","volume":"140","author":"X Yi","year":"2017","unstructured":"Yi X, Ma J, Guan Y, Chen R, Yang L, Xia X. The feasibility of using mutation detection in ctDNA to assess tumor dynamics. Int J Cancer. 2017;140(12):2642\u20137.","journal-title":"Int J Cancer"},{"issue":"10","key":"7516_CR9","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1515\/cclm-2019-0142","volume":"57","author":"B Wang","year":"2019","unstructured":"Wang B, Wu S, Huang F, Shen M, Jiang H, Yu Y, et al. Analytical and clinical validation of a novel amplicon-based NGS assay for the evaluation of circulating tumor DNA in metastatic colorectal cancer patients. Clin Chem Lab Med. 2019;57(10):10.","journal-title":"Clin Chem Lab Med"},{"issue":"10","key":"7516_CR10","doi-asserted-by":"publisher","first-page":"1573","DOI":"10.3390\/cancers11101573","volume":"11","author":"M Kastrisiou","year":"2019","unstructured":"Kastrisiou M, Zarkavelis G, Pentheroudakis G, Magklara A. Clinical application of next-generation sequencing as a liquid biopsy technique in advanced colorectal Cancer: a trick or a treat? Cancers. 2019;11(10):1573.","journal-title":"Cancers."},{"issue":"5","key":"7516_CR11","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1038\/nbt.3520","volume":"34","author":"AM Newman","year":"2016","unstructured":"Newman AM, Lovejoy AF, Klass DM, Kurtz DM, Chabon JJ, Scherer F, et al. Integrated digital error suppression for improved detection of circulating tumor DNA. Nat Biotechnol. 2016;34(5):547\u201355.","journal-title":"Nat Biotechnol"},{"issue":"15","key":"7516_CR12","doi-asserted-by":"publisher","first-page":"2011","DOI":"10.1200\/JCO.2010.33.5091","volume":"29","author":"E Van Cutsem","year":"2011","unstructured":"Van Cutsem E, Kohne CH, Lang I, Folprecht G, Nowacki MP, Cascinu S, et al. Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J Clin Oncol. 2011;29(15):2011\u20139.","journal-title":"J Clin Oncol"},{"issue":"30","key":"7516_CR13","doi-asserted-by":"publisher","first-page":"3031","DOI":"10.1200\/JCO.2018.78.3183","volume":"36","author":"S Qin","year":"2018","unstructured":"Qin S, Li J, Wang L, Xu J, Cheng Y, Bai Y, et al. Efficacy and tolerability of first-line Cetuximab plus Leucovorin, fluorouracil, and Oxaliplatin (FOLFOX-4) versus FOLFOX-4 in patients with RAS wild-type metastatic colorectal Cancer: the open-label, randomized, phase III TAILOR trial. J Clin Oncol. 2018;36(30):3031\u20139.","journal-title":"J Clin Oncol"},{"issue":"7","key":"7516_CR14","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1093\/annonc\/mdq632","volume":"22","author":"C Bokemeyer","year":"2011","unstructured":"Bokemeyer C, Bondarenko I, Hartmann JT, de Braud F, Schuch G, Zubel A, et al. Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study. Ann Oncol. 2011;22(7):1535\u201346.","journal-title":"Ann Oncol"},{"issue":"2","key":"7516_CR15","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1002\/1878-0261.12023","volume":"11","author":"W Schmiegel","year":"2017","unstructured":"Schmiegel W, Scott RJ, Dooley S, Lewis W, Meldrum CJ, Pockney P, et al. Blood-based detection of RAS mutations to guide anti-EGFR therapy in colorectal cancer patients: concordance of results from circulating tumor DNA and tissue-based RAS testing. Mol Oncol. 2017;11(2):208\u201319.","journal-title":"Mol Oncol"},{"issue":"6","key":"7516_CR16","doi-asserted-by":"publisher","first-page":"1294","DOI":"10.1093\/annonc\/mdx112","volume":"28","author":"J Grasselli","year":"2017","unstructured":"Grasselli J, Elez E, Caratu G, Matito J, Santos C, Macarulla T, et al. Concordance of blood- and tumor-based detection of RAS mutations to guide anti-EGFR therapy in metastatic colorectal cancer. Ann Oncol. 2017;28(6):1294\u2013301.","journal-title":"Ann Oncol"},{"issue":"5","key":"7516_CR17","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1093\/annonc\/mdy061","volume":"29","author":"JB Bachet","year":"2018","unstructured":"Bachet JB, Bouche O, Taieb J, Dubreuil O, Garcia ML, Meurisse A, et al. RAS mutation analysis in circulating tumor DNA from patients with metastatic colorectal cancer: the AGEO RASANC prospective multicenter study. Ann Oncol. 2018;29(5):1211\u20139.","journal-title":"Ann Oncol"},{"issue":"1","key":"7516_CR18","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1093\/annonc\/mdx417","volume":"29","author":"N Normanno","year":"2018","unstructured":"Normanno N, Esposito AR, Lambiase M, Forgione L, Cardone C, Iannaccone A, et al. RAS testing of liquid biopsy correlates with the outcome of metastatic colorectal cancer patients treated with first-line FOLFIRI plus cetuximab in the CAPRI-GOIM trial. Ann Oncol. 2018;29(1):112\u20138.","journal-title":"Ann Oncol"},{"issue":"3","key":"7516_CR19","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1158\/1078-0432.CCR-09-2446","volume":"16","author":"SE Baldus","year":"2010","unstructured":"Baldus SE, Schaefer KL, Engers R, Hartleb D, Stoecklein NH, Gabbert HE. Prevalence and heterogeneity of KRAS, BRAF, and PIK3CA mutations in primary colorectal adenocarcinomas and their corresponding metastases. Clin Cancer Res. 2010;16(3):790\u20139.","journal-title":"Clin Cancer Res"},{"issue":"9","key":"7516_CR20","doi-asserted-by":"publisher","first-page":"2149","DOI":"10.1093\/annonc\/mdx330","volume":"28","author":"AR Thierry","year":"2017","unstructured":"Thierry AR, El MS, Mollevi C, Raoul JL, Guimbaud R, Pezet D, et al. Clinical utility of circulating DNA analysis for rapid detection of actionable mutations to select metastatic colorectal patients for anti-EGFR treatment. Ann Oncol. 2017;28(9):2149\u201359.","journal-title":"Ann Oncol"},{"issue":"11","key":"7516_CR21","doi-asserted-by":"publisher","first-page":"2361","DOI":"10.1002\/1878-0261.12550","volume":"1311","author":"EJ van Helden","year":"2019","unstructured":"van Helden EJ, Angus L, Menke-van der Houven van Oordt CW, Heideman DAM, Boon E, van Es SC, et al. RAS and BRAF mutations in cell-free DNA are predictive for outcome of cetuximab monotherapy in patients with tissue-tested RAS wild-type advanced colorectal cancer. Mol Oncol. 2019;1311(11):2361\u201374.","journal-title":"Mol Oncol"},{"issue":"1","key":"7516_CR22","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1186\/s13046-018-0723-5","volume":"37","author":"CB Thomsen","year":"2018","unstructured":"Thomsen CB, Hansen TF, Andersen RF, Lindebjerg J, Jensen LH, Jakobsen A. Monitoring the effect of first line treatment in RAS\/RAF mutated metastatic colorectal cancer by serial analysis of tumor specific DNA in plasma. J Exp Clin Cancer Res. 2018;37(1):55.","journal-title":"J Exp Clin Cancer Res"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-020-07516-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-020-07516-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-020-07516-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,16]],"date-time":"2021-10-16T01:20:25Z","timestamp":1634347225000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-020-07516-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,16]]},"references-count":22,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["7516"],"URL":"https:\/\/doi.org\/10.1186\/s12885-020-07516-7","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-30475\/v4","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.3.rs-30475\/v3","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.3.rs-30475\/v2","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.3.rs-30475\/v1","asserted-by":"object"}]},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,16]]},"assertion":[{"value":"23 December 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 October 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 October 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was approved by the ethics committee of Zhongshan Hospital affiliated to Fudan University (Approval No: B2017-165R) (Shanghai, China). Written informed consent was obtained from all patients.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not Applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no conflicts of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1006"}}